Interferon-alpha and interferon-gamma modulate Fas-mediated apoptosis in mitomycin-C-resistant human Tenon's fibroblasts

2013 ◽  
Vol 42 (6) ◽  
pp. 529-538 ◽  
Author(s):  
Xiao Yang Wang ◽  
Jonathan G Crowston ◽  
Andrew JR White ◽  
Hans Zoellner ◽  
Paul R Healey
Keyword(s):  
Mitomycin C ◽  
Interferon Gamma ◽  
Interferon Alpha

Resolution of conjunctival melanoma with topical interferon alpha 2b in a patient with mitomycin C intolerance

2018 ◽  
Vol 93 (11) ◽  
pp. 558-561
Author(s):  
T.A. Chaparro Tapias ◽  
A.L. Díaz Díaz ◽  
R. Secondi ◽  
H. Coy Villamil ◽  
J.C. Sánchez España
Keyword(s):  
Mitomycin C ◽  
Interferon Alpha ◽  
Conjunctival Melanoma ◽  
Interferon Alpha 2B

Phase I study of a combination of recombinant interferon-alpha and recombinant interferon-gamma in cancer patients.

1986 ◽  
Vol 4 (11) ◽  
pp. 1677-1683 ◽  
Author(s):  
R Kurzrock ◽  
M G Rosenblum ◽  
J R Quesada ◽  
S A Sherwin ◽  
L M Itri ◽  
...  
Keyword(s):  
Interferon Gamma ◽  
Interferon Alpha ◽  
Maximum Tolerated Dose ◽  
Blood Levels ◽  
Recombinant Interferon ◽  
Starting Dose ◽  
The Individual ◽  
Dose Levels ◽  
Recombinant Interferon Alpha

Combinations of interferon-alpha and interferon-gamma demonstrate synergistic antiviral and anti-proliferative activity in vitro. Therefore, we initiated a clinical study of combination interferon therapy in humans. Eighteen patients with metastatic solid tumors received daily intramuscular (IM) injections of recombinant interferon-alpha-A (IFN alfa-2a, Roferon-A; Hoffman-LaRoche, Nutley, NJ) and recombinant IFN-gamma (rIFN-gamma) for 6 weeks. The dose levels were 0.5, 1.0, 2.0, and 5.0 X 10(6) U/m2/d of each interferon. A minimum of two patients were entered sequentially at each dose level. Fever, chills, fatigue, and a greater than or equal to 50% drop in granulocyte counts were observed at all doses. Severity of symptoms corresponded to increasing dose levels. In contrast to the tachyphylaxis to these symptoms that usually develops in patients treated with the individual interferons, many patients on this study experienced persistent fever and worsening fatigue over 6 weeks. The maximum tolerated dose was 1 X 10(6) U/m2/d of each interferon. One patient with renal-cell carcinoma achieved a partial remission (duration, 3 months). Enzyme-linked immunoassay analysis in all four patients for whom complete data were available revealed that peak blood levels of IFN alfa-2a on day 22 were about tenfold higher than on day 1. Because of the possibility of cumulative toxicity, the recommended starting dose for further studies is 0.5 X 10(6) U/m2/d of each interferon, with escalation to 1.0 X 10(6) U/m2/d after 1 month if tolerance is acceptable. Phase II investigations to explore the antitumor efficacy of this regimen are planned.

In vivo effects of interferon-alpha and interferon-gamma on lipolysis and ketogenesis.

Endocrinology ◽  
1992 ◽  
Vol 131 (4) ◽  
pp. 1695-1702 ◽  
Author(s):  
R A Memon ◽  
K R Feingold ◽  
A H Moser ◽  
W Doerrler ◽  
C Grunfeld
Keyword(s):  
Interferon Gamma ◽  
Interferon Alpha ◽  
In Vivo Effects

A randomized study comparing mitomycin C, mitomycin C plus epirubicin and mitomycin C plus interferon-alpha-2 in the intravesical prophylaxis of superficial bladder tumour recurrences

1997 ◽  
Vol 64 (4) ◽  
pp. 419-421
Author(s):  
V. Serretta ◽  
V. Falletta ◽  
P. Vasile ◽  
S. Pomara ◽  
B. Piazza
Keyword(s):  
Statistical Analysis ◽  
Mitomycin C ◽  
Interferon Alpha ◽  
Randomized Study ◽  
Bladder Tumour ◽  
Intravesical Treatment ◽  
Superficial Bladder Tumour ◽  
Bladder Tumours

– After TUR of superficial bladder tumours (G1-G3, Ta-T1), 121 patients were randomized in three groups of intravesical treatment: mitomycin C alone, mitomycin C plus epirubicin, mitomycin C plus interferon-alpha-2. At a mean follow-up of 53 months, 64 patients (52.8%) showed a recurrence. A trend (p < 0.02) in favour of the combination of mitomycin C and epirubicin was evident. The higher efficacy of this association was particularly evident when patients with primary tumours were excluded from the statistical analysis.

Sign in / Sign up

Export Citation Format

Share Document